Those who cling to the belief that medicine is more a science than a commercial enterprise might consider the story of a group of drugs known as erythropoiesis-stimulating agents (ESAs) and their approval process.ESAs are routinely given to cancer patients with anaemia.  As they are genetically-engineered forms of erythropoietin (EPO), a ...